Data from trials highlight long-term disease control and quality of life improvements

First patient dosed in study of novel EP4 antagonist for advanced solid tumours

Durvalumab becomes first immunotherapy recommended for LS-SCLC patients in England and Wales

MHRA greenlights oral therapy for patients aged 12 and over with grade 2 astrocytoma

Positive orphan drug opinion supports SOM3355’s potential as first-line treatment in Europe

Merck presents phase 3 STRIDE-13 trial results at ESCMID conference in Lisbon

New phase 4 results show sustained symptom relief and improved patient outcomes

Early data reveals strong response rates in ovarian cancer cohort

New partnership aims to fast-track mRNA therapies from lab to clinic

First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex